Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Cash & Equivalents (2017 - 2025)

Catheter Precision has reported Cash & Equivalents over the past 9 years, most recently at $100000.0 for Q4 2025.

  • Quarterly Cash & Equivalents fell 96.52% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Dec 2025, down 96.52% year-over-year, with the annual reading at $100000.0 for FY2025, 96.52% down from the prior year.
  • Cash & Equivalents was $100000.0 for Q4 2025 at Catheter Precision, down from $1.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $20.6 million in Q3 2021 and troughed at $16000.0 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $5.6 million (2023), against an average of $8.2 million.
  • Year-over-year, Cash & Equivalents plummeted 99.78% in 2024 and then surged 5137.5% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $15.0 million in 2021, then grew by 5.41% to $15.9 million in 2022, then plummeted by 77.52% to $3.6 million in 2023, then fell by 19.41% to $2.9 million in 2024, then tumbled by 96.52% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Cash & Equivalents are $100000.0 (Q4 2025), $1.1 million (Q3 2025), and $838000.0 (Q2 2025).